头颈部鳞状细胞癌免疫逃逸的生物学机制及其对免疫治疗的意义
头颈部鳞状细胞癌(HNSCC)预后差,数十年来总生存(OS)未显著改善。本文综述HNSCC免疫逃逸的生物学机制及免疫治疗意义,指出靶向生长因子与免疫检查点受体的单克隆抗体(mAbs)是迄今最有前景的方向,临床前及早期试验显示疗效前所未有且不良反应轻微。
要点
- HNSCC侵袭性强,尽管细胞毒治疗与手术技术进步,OS数十年未改善。
- 免疫治疗旨在提高肿瘤识别并扩大抗肿瘤免疫应答。
- 靶向生长因子和免疫检查点受体的mAbs是当前最有前景的HNSCC免疫治疗方向。
核心结论
- HNSCC总体生存数十年未改善,亟需高效低毒的新疗法。
- 免疫治疗试图提高肿瘤识别并扩大抗肿瘤免疫应答,单克隆抗体(mAbs)靶向生长因子和免疫检查点受体是最有前景的方向。
- 临床前和早期临床试验显示mAbs疗效前所未有且不良反应轻微。
研究设计与样本
- 综述,回顾HNSCC免疫逃逸的生物学机制及免疫治疗意义。
主要发现
- HNSCC为侵袭性恶性肿瘤,发病率和死亡率高。
- 尽管细胞毒疗法和手术技术有进展,过去数十年OS未改善。
- 临床前和早期试验中,靶向生长因子和免疫检查点受体的mAbs显示出前所未有的疗效和轻微不良反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with high morbidity and mortality. Despite advances in cytotoxic therapies and surgical techniques, overall survival (OS) has not improved over the past few decades. This emphasises the need for intense investigation into novel therapies with good tumour control and minimal toxicity. Cancer immunotherapy has led this endeavour, attempting to improve tumour recognition and expand immune responses against tumour cells. While various forms of HNSCC immunotherapy are in preclinical trials, the most promising direction thus far has been with monoclonal antibodies (mAbs), targeting growth factor and immune checkpoint receptors. Preclinical and early phase trials have shown unprecedented efficacy with minimal adverse effects. This article will review biological mechanisms of immune escape and implications for immunotherapy in HNSCC.
引用
- Moy JD, Moskovitz JM, Ferris RL, et al. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer. 2017. PMID: 28324750. doi:10.1016/j.ejca.2016.12.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。